Amgen Inc (AMGN) 165.54 $AMGN
3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 5:26PM CDT
Source: Amgen via Flickr. Things have really come together nicely for biotech blue-chip stock Amgen over the last couple of years. Following a decade where its share price had essentially gone nowhere despite aggressive share buybacks, the...
AMGN: 165.54 (+6.95)
Amgen Announces Webcast of 2015 Second Quarter Financial Results
PR Newswire - Mon Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 165.54 (+6.95)
Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jul 27, 1:56PM CDT
Healthcare giants Regeneron Pharmaceuticals and Sanofi SA (ADR) treated their investors to great news over the weekend as the companies announced that they won FDA approval of their highly anticipated cholesterol-lowering medication Praluent. ...
AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
4 Stocks Spiking on Unusual Volume
at The Street - Mon Jul 27, 1:39PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
SWI: 37.57 (+0.31), ITEK: 16.76 (-0.89), AMGN: 165.54 (+6.95), URI: 65.16 (+0.44)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Global Colorectal Cancer Drugs Market 2015-2019
M2 - Mon Jul 27, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdrzz/global_colorectal) has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering. The global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019. Biologics are rapidly becoming the treatment of choice for colorectal cancer. Biologics are targeted therapy, which act only on the malignant cells and do not attack the healthy cells. The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab). These biologics together accounted for the major share of the market, and the same trend is expected to continue during the forecast period. According to the report, colorectal cancers cannot be cured by the currently available therapeutic options. In addition, if it has not metastasized, surgery would be the only option. The chances of cancer recurring near the place of origin are high. The currently available branded and generic drugs are indicated only for off-label treatment use. However, these drugs have many side effects. Hyperbilirubinemia, gastrointestinal perforation, coagulopathy, cardiotoxicity, hemorrhage, hepatotoxicity, neutropenia, proteinuria, thrombocytopenia, ischemia, soft tissue toxicity, pulmonary fibrosis, and increased mortality are some of the significant adverse side effects. Thus, a drug maker has opportunities to exploit and seek a favorable position in the market by addressing these issues. Further, the report states that many branded drugs available in the market have lost their patents or are expected to lose it during the forecast period. This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories: - Biologics - Small molecules Based on the route of administration, the market is grouped into two categories: - Oral - Parenteral Key Vendors - Amgen - Bayer - Bristol-Myers Squibb - F. Hoffmann-La Roche - Merck Serono Other Prominent Vendors - Accord Healthcare - Advenchen Laboratories - Aeterna Zentaris - AstraZeneca - Bavarian Nordic - Biothera - Boehringer Ingelheim - Daiichi Sankyo - Debiopharm - Eisai - Eli Lilly - Immodulon Therapeutics - Mologen - Mylan - Nektar Therapeutics - Oncothyreon - Otsuka Pharmaceutical - Precision Biologics - Sun Pharmaceutical - Symphogen - Taiho - Takeda - Teva - ThromboGenics - Xbiotech - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/5x...colorectal
MRK: 56.99 (-0.42), AMGN: 165.54 (+6.95), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), NKTR: 12.42 (-0.36)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), MON: 101.46 (-1.40), COP: 50.65 (-1.44), AMGN: 165.54 (+6.95), XOM: 79.26 (-0.68), SLB: 81.76 (-1.14), CELG: 132.56 (-2.34), RIG: 13.11 (-0.15), GILD: 110.54 (-2.29), DD: 56.73 (-0.21), PX: 111.82 (-1.16), CVX: 89.14 (-1.46), DOW: 45.63 (-0.34), REGN: 540.03 (-1.82)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 3.71 (unch), AZN: 32.71 (-33.05), AMGN: 165.54 (+6.95), EXEL: 5.44 (-0.15)
Global Glomerulonephritis Clinical Trials Review 2015
M2 - Mon Jul 27, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjc7bk/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Glomerulonephritis Therapeutics Clinical Trials - Regulus Therapeutics Inc. - GlaxoSmithKline plc - Celldex Therapeutics, Inc. - Anthera Pharmaceuticals Inc. - Pharmalink AB - Osprey Pharmaceuticals U.S.A., Inc. - La Jolla Pharmaceutical Company - Daiichi Sankyo Company, Limited - Bristol-Myers Squibb Company - Amgen Inc. - The National Institute of Diabetes and Digestive and Kidney Diseases - Chinese PLA General Hospital - Chinese University of Hong Kong - Columbia University - Hospital Authority - Mayo Clinic For more information visit http://www.researchandmarkets.com/research/hj...onephritis
ANTH: 11.15 (+0.34), CLDX: 24.31 (-0.10), AMGN: 165.54 (+6.95), RGLS: 8.68 (-0.49), GSK: 41.60 (+0.21), BMY: 64.30 (-1.68)
Otic Pharma Appoints Gregory J. Flesher as Chief Executive Officer
PR Newswire Europe - Mon Jul 27, 2:30AM CDT
Otic Pharma Ltd, a privately held pharmaceutical company focused on developing innovative therapies for ear, nose, and throat disorders, today announced the appointment of Gregory J. Flesher as chief executive officer and member of the company's board of directors.
AMGN: 165.54 (+6.95)
FDA OKs breakthrough cholesterol drug for high-risk patients
By MATTHEW PERRONE - AP - Fri Jul 24, 5:31PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades.
PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 3.36% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 165.54 (+6.95)
SmarTrend Watching for Potential Rebound in Shares of Amgen After 3.36% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:52PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 165.54 (+6.95)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 71.65 (-4.26), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
Earnings Growth Hard to Come By - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 24, 2:35PM CDT
Earnings Growth Hard to Come By - Earnings Preview
WFM: 40.16 (-0.27), ROP: 164.25 (-7.86), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), IP: 47.36 (-0.39), AMGN: 165.54 (+6.95), COP: 50.65 (-1.44), XOM: 79.26 (-0.68), UPS: 95.12 (+0.37), MRK: 56.99 (-0.42), EXPE: 104.92 (-0.78), DD: 56.73 (-0.21), PG: 79.97 (-0.32), CVX: 89.14 (-1.46), MA: 94.39 (-1.44)
FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
PR Newswire - Fri Jul 24, 11:40AM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and dexamethasone (KRd) for the treatment of patients with multiple myeloma who have received one to three prior lines of therapy.
AMGN: 165.54 (+6.95)
Shire's (SHPG) Q2 Earnings Lag Estimates, 2015 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 10:05AM CDT
Shire (SHPG) reported second-quarter 2015 earnings of $2.63 per ADS, up 3% year over year, but missed the Zacks Consensus Estimate of $2.82.
AGN: 326.98 (+18.77), SHPG: 259.11 (+6.54), AMGN: 165.54 (+6.95), CORT: 4.92 (+0.21)
AbbVie beats 2Q profit forecasts, but sales fall short
AP - Fri Jul 24, 7:38AM CDT
NEW YORK (AP) — Drugmaker AbbVie Inc. reported better-than-expected second-quarter profit, but its sales disappointed Wall Street.
AMGN: 165.54 (+6.95)
3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 5:26PM CDT
Source: Amgen via Flickr. Things have really come together nicely for biotech blue-chip stock Amgen over the last couple of years. Following a decade where its share price had essentially gone nowhere despite aggressive share buybacks, the...
AMGN: 165.54 (+6.95)
Amgen Announces Webcast of 2015 Second Quarter Financial Results
PR Newswire - Mon Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 165.54 (+6.95)
Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jul 27, 1:56PM CDT
Healthcare giants Regeneron Pharmaceuticals and Sanofi SA (ADR) treated their investors to great news over the weekend as the companies announced that they won FDA approval of their highly anticipated cholesterol-lowering medication Praluent. ...
AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
4 Stocks Spiking on Unusual Volume
at The Street - Mon Jul 27, 1:39PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
SWI: 37.57 (+0.31), ITEK: 16.76 (-0.89), AMGN: 165.54 (+6.95), URI: 65.16 (+0.44)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.49 (+0.58), BIIB: 309.43 (+9.40), LGND: 102.55 (+0.46), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82), EXEL: 5.44 (-0.15), CELG: 132.56 (-2.34)
Global Colorectal Cancer Drugs Market 2015-2019
M2 - Mon Jul 27, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdrzz/global_colorectal) has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering. The global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019. Biologics are rapidly becoming the treatment of choice for colorectal cancer. Biologics are targeted therapy, which act only on the malignant cells and do not attack the healthy cells. The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab). These biologics together accounted for the major share of the market, and the same trend is expected to continue during the forecast period. According to the report, colorectal cancers cannot be cured by the currently available therapeutic options. In addition, if it has not metastasized, surgery would be the only option. The chances of cancer recurring near the place of origin are high. The currently available branded and generic drugs are indicated only for off-label treatment use. However, these drugs have many side effects. Hyperbilirubinemia, gastrointestinal perforation, coagulopathy, cardiotoxicity, hemorrhage, hepatotoxicity, neutropenia, proteinuria, thrombocytopenia, ischemia, soft tissue toxicity, pulmonary fibrosis, and increased mortality are some of the significant adverse side effects. Thus, a drug maker has opportunities to exploit and seek a favorable position in the market by addressing these issues. Further, the report states that many branded drugs available in the market have lost their patents or are expected to lose it during the forecast period. This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories: - Biologics - Small molecules Based on the route of administration, the market is grouped into two categories: - Oral - Parenteral Key Vendors - Amgen - Bayer - Bristol-Myers Squibb - F. Hoffmann-La Roche - Merck Serono Other Prominent Vendors - Accord Healthcare - Advenchen Laboratories - Aeterna Zentaris - AstraZeneca - Bavarian Nordic - Biothera - Boehringer Ingelheim - Daiichi Sankyo - Debiopharm - Eisai - Eli Lilly - Immodulon Therapeutics - Mologen - Mylan - Nektar Therapeutics - Oncothyreon - Otsuka Pharmaceutical - Precision Biologics - Sun Pharmaceutical - Symphogen - Taiho - Takeda - Teva - ThromboGenics - Xbiotech - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/5x...colorectal
MRK: 56.99 (-0.42), AMGN: 165.54 (+6.95), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), NKTR: 12.42 (-0.36)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 309.43 (+9.40), AMZN: 531.41 (+1.99), MON: 101.46 (-1.40), COP: 50.65 (-1.44), AMGN: 165.54 (+6.95), XOM: 79.26 (-0.68), SLB: 81.76 (-1.14), CELG: 132.56 (-2.34), RIG: 13.11 (-0.15), GILD: 110.54 (-2.29), DD: 56.73 (-0.21), PX: 111.82 (-1.16), CVX: 89.14 (-1.46), DOW: 45.63 (-0.34), REGN: 540.03 (-1.82)
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 3.71 (unch), AZN: 32.71 (-33.05), AMGN: 165.54 (+6.95), EXEL: 5.44 (-0.15)
Global Glomerulonephritis Clinical Trials Review 2015
M2 - Mon Jul 27, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjc7bk/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Glomerulonephritis Therapeutics Clinical Trials - Regulus Therapeutics Inc. - GlaxoSmithKline plc - Celldex Therapeutics, Inc. - Anthera Pharmaceuticals Inc. - Pharmalink AB - Osprey Pharmaceuticals U.S.A., Inc. - La Jolla Pharmaceutical Company - Daiichi Sankyo Company, Limited - Bristol-Myers Squibb Company - Amgen Inc. - The National Institute of Diabetes and Digestive and Kidney Diseases - Chinese PLA General Hospital - Chinese University of Hong Kong - Columbia University - Hospital Authority - Mayo Clinic For more information visit http://www.researchandmarkets.com/research/hj...onephritis
ANTH: 11.15 (+0.34), CLDX: 24.31 (-0.10), AMGN: 165.54 (+6.95), RGLS: 8.68 (-0.49), GSK: 41.60 (+0.21), BMY: 64.30 (-1.68)
Otic Pharma Appoints Gregory J. Flesher as Chief Executive Officer
PR Newswire Europe - Mon Jul 27, 2:30AM CDT
Otic Pharma Ltd, a privately held pharmaceutical company focused on developing innovative therapies for ear, nose, and throat disorders, today announced the appointment of Gregory J. Flesher as chief executive officer and member of the company's board of directors.
AMGN: 165.54 (+6.95)
FDA OKs breakthrough cholesterol drug for high-risk patients
By MATTHEW PERRONE - AP - Fri Jul 24, 5:31PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades.
PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 3.36% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 165.54 (+6.95)
SmarTrend Watching for Potential Rebound in Shares of Amgen After 3.36% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:52PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 165.54 (+6.95)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 71.65 (-4.26), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
Earnings Growth Hard to Come By - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 24, 2:35PM CDT
Earnings Growth Hard to Come By - Earnings Preview
WFM: 40.16 (-0.27), ROP: 164.25 (-7.86), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), IP: 47.36 (-0.39), AMGN: 165.54 (+6.95), COP: 50.65 (-1.44), XOM: 79.26 (-0.68), UPS: 95.12 (+0.37), MRK: 56.99 (-0.42), EXPE: 104.92 (-0.78), DD: 56.73 (-0.21), PG: 79.97 (-0.32), CVX: 89.14 (-1.46), MA: 94.39 (-1.44)
FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
PR Newswire - Fri Jul 24, 11:40AM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and dexamethasone (KRd) for the treatment of patients with multiple myeloma who have received one to three prior lines of therapy.
AMGN: 165.54 (+6.95)
Shire's (SHPG) Q2 Earnings Lag Estimates, 2015 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 10:05AM CDT
Shire (SHPG) reported second-quarter 2015 earnings of $2.63 per ADS, up 3% year over year, but missed the Zacks Consensus Estimate of $2.82.
AGN: 326.98 (+18.77), SHPG: 259.11 (+6.54), AMGN: 165.54 (+6.95), CORT: 4.92 (+0.21)
AbbVie beats 2Q profit forecasts, but sales fall short
AP - Fri Jul 24, 7:38AM CDT
NEW YORK (AP) — Drugmaker AbbVie Inc. reported better-than-expected second-quarter profit, but its sales disappointed Wall Street.
AMGN: 165.54 (+6.95)
